As the coronavirus (COVID-19) outbreak develops, the United States faces drug and medical supply scarcities due to disrupted supply chains and increased demand. In response, the President may exercise emergency authorities under the Defense Production Act of 1950 (DPA; 50 U.S.C. §§4501 et seq.) to address supply shortages and economic development impacts, and may have begun the process of doing so. This Insight considers DPA authorities that may be used to address domestic essential goods and materials shortages caused by the outbreak, and explores potential policy considerations for Congress. For more information on the health and epidemiological aspects of COVID-19, see CRS products R46219 and IF11421.
The DPA confers broad presidential authorities to mobilize domestic industry in service of the national defense, defined in statute as various military activities and "homeland security, stockpiling, space, and any directly related activity" (50 U.S.C. §4552.) including emergency preparedness activities under the Stafford Act, which has been used for public health emergencies. Many of these authorities are delegated to executive agencies under Executive Order 13603.
Current DPA authorities include, but are not limited to:
For a more in-depth discussion of DPA authorities, see CRS Report R43767.
As the DPA's definition of national defense encompasses homeland security issues, the DPA could potentially be used to respond to public health emergencies, though this has not occurred before. At the President's discretion, DPA authorities could be employed to address concerns over medical supplies shortages due to the COVID-19 outbreak.
As an example of how DPA authorities could be exercised, consider the availability of personal protective equipment (PPE), such as respirator masks, amid the outbreak. Reported PPE shortages may be due to significantly increased consumer demand related to the outbreak itself, and supply chain disruptions resulting from containment measures in China and elsewhere.
Under Title I, the President could prioritize domestic production of PPE to ensure sufficient national stockpiles, and allocate them according to the needs of the emergency. Under Title III, the federal government could use authorized incentives to expand domestic capacity for PPE manufacturing to meet the needs of the emergency. Under Title VII, the President could establish voluntary agreements with private industry—which might normally be subject to anti-trust statutes—to coordinate industry PPE production.
The decision whether to employ DPA authorities generally lies with the President. However, in addition to Congress's inherent oversight authority, the DPA statute outlines several specific congressional equities:
However, the DPA confers broad waivers to its Title III requirements:
During a period of national emergency declared by Congress or the President; or upon determination by the President, on a nondelegable basis, that action is necessary to avert an industrial resource or critical technology item shortfall that would severely impair national defense capability. (50 U.S.C. §4531(d)(1)(B))
Another area of possible congressional interest is DPA funding, which is appropriated annually. The FY2020 appropriation to the DPA fund was $64.4 million; the President's FY2021 budget requested $182 million for the DPA fund (p. 276). DPA appropriations could also be made as part of a supplemental appropriations package if the DPA fund is exhausted and/or to provide resources for other DPA authorities.